In 2011, the foundation awarded three-year grants of $486,000 each to nine projects that have the potential to accelerate breakthroughs in the treatment of sickle cell disease.
2011 ICRA Grantees
Seth L. Alper, M.D., Ph.D.
Beth Israel Deaconess Medical Center
Project name: Molecular Identification and Inhibition of the Deoxygenation-Activated, Calcium-Permeable Cation Channel of The Sickle Erythrocyte, Psickle, a Novel Therapeutic Target for Treatment of Sickle Disease
Jen-Tsan A. Chi, M.D., Ph.D., and Marilyn J. Telen, M.D.
Project name: NRF2 Induction as Novel Treatment for Sickle Cell Disease
Stella T. Chou, M.D., and Connie M. Westhoff, Ph.D.
Children's Hospital of Philadelphia and New York Blood Center
Project name: Genomic Approaches to Prevent Red Blood Cell Alloimmunization in Patients with Sickle Cell Disease
George Q. Daley, M.D., Ph.D.
Children's Hospital Boston
Project name: Modeling Sickle Cell Anemia with Induced Pluripotent Stem Cells
Joshua J. Field, M.D., M.S., and Jonathan Lindner, M.D.
The Medical College Of Wisconsin, Inc. and Oregon Health Sciences University
Project name: Effects of the Adenosine 2A Receptor Agonist Regadenoson on Sickle Cell Vaso-occlusion and Inflammation
Peter M. Glazer, M.D., Ph.D.
Project name: Nanoparticle-Mediated Correction of the Sickle Cell Disease Mutation
Antonio Guasch, M.D., and Marianne E.M. Yee, M.D., M.Sc.
Project name: Reversal of Sickle Cell-Related Chronic Kidney Disease
Carolyn C. Hoppe, M.D., M.P.H.
Children's Hospital and Research Center Oakland
Project name: Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Michel Sadelain, M.D., Ph.D., and Patricia A. Shi, M.D., MS
Memorial Sloan-Kettering Cancer Center and New York Blood Center
Project name: Preclinical Evaluation of Globin Gene Transfer in Mobilized SCD Patient CD34+ Cells